Open AccessFibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas
Author(s) -
Eva Wimmer,
Stephan Ihrler,
Olivier Gires,
Sylvia Streit,
W. J. Issing,
Christoph Bergmann
Publication year - 2019
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v10.i3.136
Subject(s) - fibroblast growth factor receptor 4 , head and neck squamous cell carcinoma , medicine , single nucleotide polymorphism , snp , fibroblast growth factor receptor , receptor tyrosine kinase , immunohistochemistry , oncology , pathology , head and neck cancer , survival analysis , cancer research , genotype , cancer , receptor , biology , fibroblast growth factor , gene , genetics
Head and neck squamous cell carcinoma (HNSCC) is considered to be a progressive disease resulting from alterations in multiple genes regulating cell proliferation and differentiation like receptor tyrosine kinases (RTKs) and members of the fibroblast growth factor receptors (FGFR)-family. Single-nucleotide polymorphism (SNP) Arg388 of the FGFR4 is associated with a reduced overall survival in patients with cancers of various types. We speculate that FGFR4 expression and SNP is associated with worse survival in patients with HSNCC.